Studies have demonstrated that the integration of genomic and proteomic data has been successfully applied in the context of non-small cell lung cancer (NSCLC), where mutations in the EGFR gene have been shown to correlate with specific protein expression patterns that predict responsiveness to EGFR tyrosine kinase inhibitors [131]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.